logo BDSP

Base documentaire


Votre avis nous intéresse

Le réseau BDSP met en oeuvre un projet d'innovation et d'amélioration de ses services, dans le souci constant de proposer des contenus de qualité adaptés aux besoins des utilisateurs.

Identifier de nouvelles sources de financements est la condition nécessaire pour assurer la poursuite et la pérennité de cet outil unique qu'est la BDSP, tout en le faisant évoluer.

Pour définir un nouveau modèle économique, nous avons besoin de votre avis : merci de répondre à notre enquête (temps estimé : 5 minutes).

Participer maintenant
Participer plus tard J'ai déjà participé

  1. European randomized study of prostate cancer screening : first-year results of the Finnish trial.

    Article - En anglais

    Approximately 20 000 men 55-67 years of age from two areas in Finland were identified from the Population Registry and randomized either to the screening arm (1/3) or the control arm (2/3) of a prostate cancer screening trial.

    In the first round, the participation rate in the screening arm was 69%. Of the 5053 screened participants, 428 (8.5%) had a serum prostate-specific antigen (PSA) concentration of 4.0 ng/ml or higher, and diagnostic examinations were performed on 399 of them.

    A total of 106 cancers were detected among them corresponding to a positive predictive value of 27%, which is comparable with mammography screening for breast cancer.

    The prostate cancer detection rate based on a serum PSA concentration of 4.0 ng ml-1 or higher was 2.1%. Approximately nine out of ten screen-detected prostate cancers were localized (85% clinical stage T1-T2) and well or moderately differentiated (42% World Health Organization (WHO) grade I and 50% grade II), which suggests a higher proportion of curable cancers compared with cases detected by other means.

    Mots-clés Pascal : Tumeur maligne, Prostate, Antigène spécifique prostate, Marqueur tumoral, Dépistage, Randomisation, Finlande, Europe, Homme, Appareil génital mâle pathologie, Appareil urinaire pathologie, Prostate pathologie

    Mots-clés Pascal anglais : Malignant tumor, Prostate, Prostate specific antigen, Tumoral marker, Medical screening, Randomization, Finland, Europe, Human, Male genital diseases, Urinary system disease, Prostate disease

    Logo du centre Notice produite par :
    Inist-CNRS - Institut de l'Information Scientifique et Technique

    Cote : 99-0145055

    Code Inist : 002B14D02. Création : 16/11/1999.